Cresco Labs: Analyst Expectations For Q2 2021

Cresco Labs (CSE: CL) announced that they will be reporting their second quarter financials before the market opens on August 13.

Analysts have a consensus C$23.31 12-month price target on the company, via a total of 17 analysts, with 5 analysts having a strong buy rating, 11 analysts have a buy rating and a single analyst has a hold rating. The street high comes in at a C$36 price target, and the lowest target comes in at a C$13.66 price target.

13 analysts have revenue estimates for the second quarter. The mean between all 13 is $194.72 million; this number has been the same since the start of the year. The street high is $216.20 million while the lowest sits at $187 million.

8 analysts have estimates for what this quarter’s gross profit margin will be. They expect the profit margin to come in at 50.65%, with this number being revised slightly higher from 49.25% at the start of the year. Street high goes to Beacon Securities with a 52% estimate and the lowest sits at 50%.

Onto EBITDA estimates, there are currently 131analysts who have second quarter EBITDA estimates. The mean is currently $44.56 million, with this number being lower than at the start of the year. Street high goes to ATB Capital Markets with a $47.30 million EBITDA estimate and the lowest being a $40.99 million estimate.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

This Copper Mine Costs 1/6 to Restart | SSR Mining X Roxmore

Why Cambria Hit Pause on Its Massive Copper-Gold Spinout

Can Gold Rescue Washington From Its Debt Trap? | Andy Schectman – Miles Franklin

Recommended

Blue Jay Gold Signs Ocean Partners Deal to Ship Steller Stockpiles Through 2027

Krait Critical Minerals Signs Option for Historical Nevada King Antimony Mine

Related News

Curaleaf Sees Consensus Estimates Stay Flat After Q1 Results

Curaleaf Holdings (CSE: CURA) reported its first-quarter results on May 10th, beating the consensus estimates...

Saturday, May 15, 2021, 04:24:00 PM

Fortuna Silver Sees BMO Cut Price Target To $6.50 Following Mixed Q4 Results

In late March Fortuna Silver Mines Inc. (TSX: FVI) reported its fourth quarter and full-year...

Saturday, April 2, 2022, 11:06:00 AM

Canaccord Drops Medmen Price Target To $0.00, Reiterates Sell Rating

After Medmen Enterprises’ (CSE: MMEN) fourth-quarter results dropped after hours on October 15th, Canaccord downgraded...

Friday, October 16, 2020, 12:22:53 PM

Columbia Care: Canaccord Reiterates Top Pick Following Green Leaf Medical Acquisition

Last Friday, Columbia Care Inc. (CSE: CCHW) closed their acquisition of Green Leaf Medical which...

Friday, June 18, 2021, 01:30:00 PM

AMD: Analysts Raise Estimates, Markets Shrug Following Earnings

Advanced Micro Devices (NASDAQ: AMD) opened 3% higher but ultimately closed down 1.4% the day...

Friday, April 30, 2021, 03:41:00 PM